Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00554385 · ClinicalTrials.gov registry record · Phase 2

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 2 study, sponsored by Abbott.

Terminated
Registry status
Phase 2
Development phase
283
Enrollment target

NCT00554385: Clinical Trial Phase 2 study, sponsored by Abbott.

NCT00554385 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 283 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (113% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00554385, a Phase 2 study, was terminated before completion, sponsored by Abbott.

TERMINATED
Registry status
Phase 2
Development phase
283 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.

Interventions

  • DRUG ABT-089

Trial Details

FieldValue
Enrollment Target 283 participants
Start Date 2007-11
Phase Phase 2
Abbott

181 total trials

Why NCT00554385 stopped before completion

NCT00554385 is an interventional study that assigns participants to a tested intervention. The registered 283 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (113% higher).

The record links to 0 conditions, and to 1 intervention - of which ABT-089 is the first listed.

NCT00554385 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00554385 about?

NCT00554385 is a clinical study titled "A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)". The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.

What is the current status of trial NCT00554385?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 283 participants. The study started on 2007-11.

What interventions are being tested in trial NCT00554385?

The interventions under investigation include: ABT-089 (DRUG).

Who is sponsoring clinical trial NCT00554385?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00554385's enrollment target sits among peer trials

283 195th of 2000 higher than 1,806 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06856694 · 283 participants · NA

    RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer

  • NCT05263206 · 284 participants · Phase 3

    Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

  • NCT05769218 · 284 participants · NA

    PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study

  • NCT06856577 · 284 participants · Phase 3

    Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00554385, the US trial registry maintained by the National Library of Medicine. NCT00554385 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.